Neumora Therapeutics is abandoning its lead depression drug after two more Phase 3 clinical trials ended in failure, the company announced. The setback also triggered a significant round of layoffs, with 35% of the company's staff set to lose their jobs, according to Endpoints News.
The failures mark the latest in a string of painful updates for the biotech, which had positioned itself as a serious player in neuroscience drug development. Endpoints News, which broke the story, described the company — founded with considerable fanfare around a neuroscience-focused pipeline — as "proving to be a Really Big Flop with each passing update."
Phase 3 trials are the final, most rigorous stage of clinical testing before a drug can seek regulatory approval. Failing at this stage is costly in every sense: years of research, hundreds of millions of dollars in investment, and the hopes of patients with treatment-resistant depression can all come undone in a single data readout. Two failures of the same drug in Phase 3 leaves little room for recovery.
Neuroscience has long been considered one of the hardest areas in drug development, with an unusually high failure rate even by the standards of an industry where most experimental medicines never reach patients.
The story matters because it underscores how brutal the drug development pipeline remains, even for well-funded biotechs targeting diseases — like depression — that desperately need new treatments.